Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years

This paper reports the data concerning the net economic cost savings attributable to influenza vaccination in healthy children aged 2–5 years, and may be useful when deciding the best recommendations for the use of influenza vaccine in pediatrics.A total of 303 previously unprimed healthy children aged 2–5 years (163 males; mean age ± S.D.: 3.22 ± 2.43 years) were prospectively, blindly randomised in a 2:1 ratio to receive two doses of an inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland) or no vaccination. The results show that influenza vaccination of healthy children aged 2–5 years substantially reduces influenza-like illnesses and related costs in the children themselves and their families. However, larger and longer running study spanning multiple seasons may be warranted before suggesting the universal vaccination of this group of subjects.